Kane Biotech and the U.S. Army Institute of Surgical Research Sign Extension of Cooperative Research and Development Agreement

- July 31st, 2018

Kane Biotech (TSXV:KNE) has announced a three-year cooperative research and development agreement extension has been signed with the US Army Institute of Surgical Research in Houston, Texas. As quoted in the press release: The primary objective of this collaboration on “Treatments to Prevent Biofilm Formation for Promoting Wound Healing” is to develop an antibiofilm-antimicrobial wound … Continued

Kane Biotech (TSXV:KNE) has announced a three-year cooperative research and development agreement extension has been signed with the US Army Institute of Surgical Research in Houston, Texas.

As quoted in the press release:

The primary objective of this collaboration on “Treatments to Prevent Biofilm Formation for Promoting Wound Healing” is to develop an antibiofilm-antimicrobial wound gel formulation and test the said gel formulation to address the needs of the United States Army Dental and Trauma Research Detachment’s (USADTRD) programs and that can be readily translated into clinical testing for improving the outcomes of wounded casualties.

The mission of USADTRD is to provide military relevant research and solutions to treat and rehabilitate craniomaxillofacial trauma and prevent infectious disease. The USADTRD’s Biofilm Impaired Wound Healing program focuses on providing algorithms to understand biofilm pathophysiology and test agents useful to treat not only dental biofilm (plaque) and combat wounds-associated biofilm infections, but also to provide antimicrobials for the control of dental plaque-associated oral infections.

Mark Ahrens-Townsend, President & CEO commented, “The extension of the CRADA with the U.S. Army is good news for Kane Biotech.  Work previously completed with the USAISR and USADTRD involving Kane Biotech’s DispersinB® anti-biofilm enzyme yielded promising results. Over the past 18 months Kane Biotech has made significant advances with DispersinB® in the areas of formulation, stability and at scale manufacturing levels. We are eager to see this opportunity move forward for both Kane Biotech and the U.S. Army.”

A study published in Current Microbiology1 “… provides the in vitro evidence to support the use of a novel combination of DispersinB®antibiofilm enzyme that inhibits biofilm formation and disperses preformed biofilm, and thus making the biofilm bacteria more susceptible to a broad-spectrum KSL-W antimicrobial peptide.”

Click here to read the full press release.

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Tags

Leave a Reply